Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3 treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or c)placebo. The anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Hot Springs, Arkansas, United States
Little Rock, Arkansas, United States
Santa Monica, California, United States
Alpharetta, Georgia, United States
East Windsor, New Jersey, United States
Albuquerque, New Mexico, United States
New York, New York, United States
New York, New York, United States
Stony Brook, New York, United States
Winston-Salem, North Carolina, United States
Start Date
July 1, 2007
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
November 2, 2016
66
ACTUAL participants
Placebo
DRUG
RG3421 120mg
DRUG
RG3421 20mg
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions